Loading...
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-r...
Saved in:
| Published in: | Lancet Oncol |
|---|---|
| Main Authors: | , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5702534/ https://ncbi.nlm.nih.gov/pubmed/27924752 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(16)30406-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|